In lipid-laden HepG2 cells and HFD-induced NAFLD mouse models, Gal-LNP-RSV exhibited superior therapeutic efficacy, effectively reducing hepatic lipid accumulation, restoring serum ALT/AST levels, and ameliorating oxidative stress. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.